The increasing complexity of modern therapeutics has significantly accelerated demand for peptide contract manufacturing market solutions, oligonucleotide manufacturing services, and broader CDMO pharmaceutical outsourcing models. As pharmaceutical companies focus more on innovation and less on in-house production, Contract Development and Manufacturing Organizations (CDMOs) are becoming critical partners in advancing peptide- and nucleic acid-based drug pipelines. This shift is strongly driving the expansion of the Peptide and Oligonucleotide CDMO Market, which continues to play a pivotal role in next-generation drug development.

The Peptide and Oligonucleotide CDMO Market was valued at USD 3.5 billion in 2024 and is projected to reach USD 4 billion in 2025. Driven by strong demand for peptide and nucleic acid-based therapeutics, the market is expected to grow at a CAGR of 15.1% from 2025 to 2034, reaching approximately USD 14.2 billion by 2034.

Peptide Contract Manufacturing Market Strengthens Biopharmaceutical Production

The peptide contract manufacturing market is expanding rapidly as peptides become increasingly important in treating metabolic disorders, cancer, infectious diseases, and hormonal conditions. Peptide-based drugs offer high specificity, strong biological activity, and reduced toxicity, making them a preferred modality in modern drug development.

Peptide CDMOs provide end-to-end services, including solid-phase peptide synthesis (SPPS), purification, analytical testing, and GMP-scale manufacturing. These services enable pharmaceutical companies to scale from early research to full commercial production without investing heavily in infrastructure.

Growing approvals of peptide therapeutics, especially in oncology and endocrinology, are further fueling demand for scalable and high-quality peptide manufacturing services globally.

Oligonucleotide Manufacturing Services Drive Next-Generation Therapies

Oligonucleotide manufacturing services are gaining significant traction due to the rapid rise of RNA-based therapeutics, antisense oligonucleotides (ASOs), siRNA drugs, and gene-silencing technologies. These therapies are transforming treatment approaches for genetic disorders, rare diseases, and certain cancers.

Manufacturing oligonucleotides requires high precision, advanced purification techniques, and strict quality control to ensure stability and efficacy. CDMOs play a crucial role in providing scalable solutions for research, clinical, and commercial-grade oligonucleotides.

Recent advancements in nucleic acid chemistry, automated synthesis platforms, and purification technologies have significantly improved production efficiency. This has enabled faster development timelines and increased accessibility of oligonucleotide-based therapies.

CDMO Pharmaceutical Outsourcing Accelerates Industry Transformation

The rise of CDMO pharmaceutical outsourcing is reshaping the global pharmaceutical value chain. Companies are increasingly outsourcing drug development and manufacturing to specialized CDMOs to reduce costs, improve efficiency, and access advanced technical expertise.

CDMOs offer integrated services that span drug discovery support, process development, analytical testing, scale-up manufacturing, and regulatory support. This allows pharmaceutical companies to focus on core competencies such as research, clinical development, and commercialization.

Outsourcing is especially important in the peptide and oligonucleotide sectors due to the high complexity of synthesis, stringent regulatory requirements, and need for specialized facilities. As a result, CDMOs have become strategic partners in accelerating time-to-market for innovative therapies.

Peptide and Oligonucleotide CDMO Market Expands with Technological Innovation

The Peptide and Oligonucleotide CDMO Market is witnessing strong expansion driven by increasing investment in biologics, nucleic acid therapeutics, and precision medicine. The growing demand for targeted therapies is pushing pharmaceutical companies to rely more heavily on specialized CDMO providers.

Technological advancements such as automated synthesis systems, continuous manufacturing, and advanced purification techniques are improving efficiency and scalability. These innovations are enabling CDMOs to support complex molecules with higher yield, purity, and consistency.

Additionally, increasing regulatory compliance requirements and the need for high-quality GMP manufacturing are strengthening the role of CDMOs in global drug production.

Segment Analysis

Within the Peptide and Oligonucleotide CDMO Market, the peptide segment holds a significant share due to its widespread application in metabolic and oncology therapeutics. Peptides are increasingly used in GLP-1 receptor agonists, hormone therapies, and targeted cancer treatments.

The oligonucleotide segment is expected to witness the fastest growth, driven by rising demand for RNA-based drugs, gene silencing therapies, and personalized medicine approaches. Additionally, the contract manufacturing segment dominates due to increasing outsourcing of large-scale production by pharmaceutical companies. 

Discover the Complete Report Here:

https://www.polarismarketresearch.com/industry-analysis/peptide-and-oligonucleotide-cdmo-market

Some of the major players operating in the global peptide and oligonucleotide CDMO market include:

• Aurigene Pharmaceutical Services Ltd.
• Bachem Group
• CordenPharma
• Creative Peptides
• Curia Global, Inc.
• EUROAPI
• Genscript Biotech Corporation
• Lonza Group
• Merck KGaA
• PolyPeptide Group
• Senn Chemicals AG
• STA Pharmaceutical Co. Ltd.
• Sylentis, S.A.
• Thermo Fisher Scientific Inc.
• Wuxi AppTec

Regional Analysis

North America leads the Peptide and Oligonucleotide CDMO Market due to strong biopharmaceutical infrastructure, high R&D investment, and early adoption of advanced therapeutic technologies. The United States remains a global hub for peptide and oligonucleotide drug development.

Europe also holds a significant market share, supported by strong regulatory frameworks, expanding biotechnology sector, and increasing collaborations between pharmaceutical companies and CDMOs. Meanwhile, Asia Pacific is expected to grow at the fastest rate due to cost-effective manufacturing, expanding pharmaceutical production capabilities, and increasing outsourcing activities in countries such as China and India.

Future Outlook

The future of the Peptide contract manufacturing market, oligonucleotide manufacturing services, and CDMO pharmaceutical outsourcing is closely linked to the increasing demand for complex biologics and precision medicines. As pharmaceutical pipelines become more advanced, reliance on specialized CDMO partners will continue to grow.

Continuous innovation in synthesis technologies, automation, and scalable manufacturing platforms will further enhance production efficiency and reduce costs. With rising global demand for peptide- and nucleic acid-based therapies, the Peptide and Oligonucleotide CDMO Market is expected to experience sustained long-term growth, playing a critical role in shaping the future of modern pharmaceutical manufacturing.

More Trending Latest Reports By Polaris Market Research:

Asthma Treatment Market

Orthopedic Devices Market

North America SGLT2 Inhibitors Market

Medical Examination Lights Market

Diaphragm Pacing Therapy System Market

Biguanides Market

Manual Resuscitators Market

Coagulation Reagent Market